Patents by Inventor BRUCE E. SELIGMANN

BRUCE E. SELIGMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Molecular malignancy in melanocytic lesions
    Patent number: 9758829
    Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: September 12, 2017
    Assignees: HTG Molecular Diagnostics, Inc., John Wayne Cancer Institute
    Inventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Tom Vasicek, B J Kerns, Bruce E. Seligmann, Dave S. B. Hoon
  • MOLECULAR MALIGNANCY IN MELANOCYTIC LESIONS
    Publication number: 20150176072
    Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.
    Type: Application
    Filed: June 24, 2013
    Publication date: June 25, 2015
    Applicants: HTG Molecular Diagnostics, INc., John Wayne Cancer Institute
    Inventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Justin Brown, Tom Vasicek, BJ Kerns, Bruce E. Seligmann, Dave S.B. Hoon
  • QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND SEQUENCING (QNPS) IMPROVEMENTS
    Publication number: 20140235460
    Abstract: The present disclosure provides an improvement to quantitative Nuclease Protection Assay (qNPA) and quantitative Nuclease Protection Sequencing (qNPS) methods. The disclosed methods use nuclease protection probes (NPPs) that include 5?-end and/or 3-end flanking sequences, which provide a universal hybridization and/or amplification sequence. The disclosed methods can be used to sequence or detect target nucleic acid molecules, such as those present in fixed or insoluble samples.
    Type: Application
    Filed: May 1, 2014
    Publication date: August 21, 2014
    Applicant: HTG Molecular Diagnostics, Inc.
    Inventors: Debrah Thompson, Bruce E. Seligmann, Debra A. Gordon
  • QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND SEQUENCING (QNPS) IMPROVEMENTS
    Publication number: 20140087954
    Abstract: The present disclosure provides an improvement to quantitative Nuclease Protection Assay (qNPA) and quantitative Nuclease Protection Sequencing (qNPS) methods. The disclosed methods use nuclease protection probes (NPPs) that include 5?-end and/or 3-end flanking sequences, which provide a universal hybridization and/or amplification sequence. The disclosed methods can be used to sequence or detect target nucleic acid molecules, such as those present in fixed or insoluble samples.
    Type: Application
    Filed: April 26, 2012
    Publication date: March 27, 2014
    Applicant: HTG Molecular Diagnostics, Inc.
    Inventors: Bruce E. Seligmann, Debrah Thompson, Tom Vasicek, Debra A. Gordon
  • COMPOSITIONS AND METHODS FOR ALK MOLECULAR TESTING
    Publication number: 20130288915
    Abstract: Disclosed herein are methods of predicting response of a tumor to an ALK inhibitor and methods of determining diagnosis or prognosis of a subject with a tumor. The methods can include detecting presence of an ALK gene fusion (such as EML4-ALK, TFG-ALK, or KIF5B-ALK) in a sample from a subject. Also disclosed herein are arrays for detecting the presence of ALK and/or ROS1 gene fusions in a sample. In some embodiments, the array includes one or more oligonucleotides complementary to an ALK or ROS1 gene fusion.
    Type: Application
    Filed: April 3, 2013
    Publication date: October 31, 2013
    Applicant: HTG MOLECULAR DIAGNOSTICS, INC.
    Inventors: BRUCE E. SELIGMANN, BJ KERNS, MARK SCHWARTZ, JOHN W. LUECKE